Carvedilol EP IMpurity E

CAS No. 64464-07-9

Carvedilol EP IMpurity E( —— )

Catalog No. M15446 CAS No. 64464-07-9

Used as pharmaceutical intermediates.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
25MG 32 In Stock
50MG 47 In Stock
100MG 70 In Stock
200MG Get Quote In Stock
500MG 170 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Carvedilol EP IMpurity E
  • Note
    Research use only, not for human use.
  • Brief Description
    Used as pharmaceutical intermediates.
  • Description
    Used as pharmaceutical intermediates.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    64464-07-9
  • Formula Weight
    203.67
  • Molecular Formula
    C9H13NO2·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    Limited solubility
  • SMILES
    Cl.COC1=CC=CC=C1OCCN
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Neuromedin (U25), hu...

    Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds.

  • Arctiin

    Arctiin(NSC 315527), a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compound and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.

  • RMC-6291

    RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .